Why Your Literature Review Was Already Outdated Before Submission

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

The MDR does not allow clinical evaluation to be a static exercise. Article 61 requires that clinical evaluation be continuously updated throughout the device lifecycle. This is not a recommendation. It is a regulatory requirement.

Yet most manufacturers treat literature reviews as one-time tasks. They search once, analyze once, document once, and move on. The problem surfaces when the CER is submitted six months later, when a new comparable device receives an incident alert, or when the first periodic safety update report reveals data that contradicts the original conclusions.

The question is not whether you should update your literature review. The question is: what triggers an update, and how do you prove you stayed current?

The Regulatory Expectation for Currency

Article 61(11) of the MDR explicitly requires that clinical evaluation be updated throughout the lifecycle of the device. MDCG 2020-6 reinforces this by stating that manufacturers must actively monitor new clinical data and incorporate relevant findings into their clinical evaluation.

This expectation goes beyond PMCF. PMCF generates new data about your device. But your literature review must also remain current about devices used for equivalence, alternative treatment options, the state of the art, and emerging risks in the therapeutic area.

When a Notified Body reviews your CER, one of the first checks is the search date of your literature review. If the search is old, the reviewer will ask: what happened between then and now? Did you check? Did anything change?

If you cannot answer, the file stops.

What Triggers a Literature Review Update

Not every day requires a new literature search. But certain events should always trigger a review of whether your literature base is still valid. These triggers fall into several categories.

Device-Related Triggers

Any change to your device that could affect safety or performance should trigger a re-evaluation of your literature review. This includes design changes, material changes, changes in intended use, or expansion into a new patient population.

Why? Because the existing literature may not cover the new configuration. If you modify the coating on a vascular stent, literature on the previous coating may no longer be relevant. If you extend indications to pediatric patients, adult data alone may not be sufficient.

The same applies to changes in equivalent devices used in your clinical evaluation. If a device you cited as comparable is modified, withdrawn, or subject to a field safety corrective action, your equivalence claim may no longer be valid. Your literature review must reflect this.

Regulatory and Market Triggers

Field safety notices, recalls, incident trends reported through EUDAMED, or safety communications from competent authorities are all triggers. If an incident pattern emerges for your device or for similar devices, you must assess whether new literature addresses the issue.

This is where many manufacturers fail. They monitor their own vigilance data, but they do not systematically track safety signals for comparable devices or for the device category. When a significant safety issue surfaces elsewhere, the literature review may contain evidence that was overlooked.

New regulatory guidance can also trigger an update. If MDCG publishes new expectations on clinical evidence for a specific device category, you may need to search for additional data to meet those expectations.

Time-Based Triggers

Even without specific events, time alone can be a trigger. If your literature search is more than twelve months old and you are submitting a new CER, most reviewers will expect you to justify why you did not perform an update search.

Some therapeutic areas evolve faster than others. In rapidly advancing fields like digital health, machine learning algorithms, or novel biomaterials, a twelve-month gap is significant. In more stable fields, the threshold may be longer. But the burden is on you to justify currency.

This does not mean you must repeat the entire search protocol every year. It means you must perform an update search using the same strategy and assess whether new data changes your conclusions.

PMCF-Driven Triggers

Your PMCF activities generate data continuously. When PMCF results reveal unexpected outcomes, higher complication rates than anticipated, or performance issues, you must revisit the literature to understand whether these findings align with the broader clinical evidence.

If your PMCF shows a complication rate that contradicts the literature you cited, you have two possibilities: either your device behaves differently, or the literature was not representative. Both scenarios require action.

This feedback loop between PMCF and literature review is rarely formalized. Manufacturers treat them as separate activities. But they are interconnected. PMCF informs whether your literature review remains valid.

How to Structure Update Searches

An update search is not a completely new search. It is a continuation of the original search protocol, limited to the period since the last search date.

You use the same databases, the same search terms, the same inclusion and exclusion criteria. The only difference is the date range. This ensures consistency and traceability.

The results must be documented in the same way as the original search. You record the number of hits, apply your screening process, and assess whether any new publications are relevant to your clinical evaluation.

If no new relevant data is found, you document that. The statement that no significant new clinical data was identified since the last search date is acceptable, as long as it is supported by evidence that you actually searched.

If new data is found, you assess its impact. Does it support your conclusions? Does it contradict them? Does it introduce a new risk or a new benefit? The CER must be updated accordingly.

Documenting Your Update Process

The challenge is not only performing updates. It is proving that you performed them at the right moments and that you acted on the findings.

This requires a documented process. You need a procedure that defines what triggers an update, who is responsible for conducting it, and how the results feed back into the CER and the technical documentation.

Most manufacturers do not have this. They update the CER when forced to, usually before a recertification audit or a significant change notification. But there is no systematic approach.

A proper process includes a trigger log. Every time a potential trigger occurs—design change, safety notice, PMCF finding, time threshold—it is recorded. The clinical evaluation team assesses whether an update is necessary. If yes, the update is performed. If no, the rationale is documented.

This log becomes part of your clinical evaluation documentation. It shows the Notified Body that you are managing currency proactively, not reactively.

What Auditors Look For

When a Notified Body audits your clinical evaluation process, they will check several things related to currency:

First, they will check the date of the last literature search against the submission date. If the gap is large, they will ask for justification.

Second, they will check whether you have a defined process for triggering updates. If updates only happen sporadically or when someone remembers, that signals weak quality management.

Third, they will check whether updates actually led to action. If you identified new relevant data but did not incorporate it into the CER, that is a major nonconformity.

Finally, they will check consistency across documents. If your PMCF plan references a literature review version from two years ago, but your CER claims to be current, that contradiction will be flagged.

The Practical Reality of Managing Currency

I understand the practical challenge. Clinical evaluation is resource-intensive. Searching, screening, appraising, and synthesizing literature takes time. Doing it repeatedly seems inefficient.

But the alternative is worse. If you submit outdated clinical evidence, the review stops. If a safety issue emerges and you missed the literature that predicted it, your risk management credibility collapses. If your equivalent device is recalled and you did not know, your entire equivalence strategy fails.

The solution is not to search constantly. The solution is to define clear triggers, apply them systematically, and document your reasoning.

Some updates will be quick. A targeted search covering six months may return no relevant results. That takes hours, not weeks. Other updates will be significant and require deeper analysis. But at least you know when to invest that effort.

The worst approach is avoidance. Hoping the Notified Body will not ask. Assuming nothing changed. Treating the literature review as a document rather than a living process.

The Link to State of the Art

Currency also connects to your state of the art analysis. The state of the art is not static. It evolves with new clinical evidence, new technologies, and new safety information.

If your literature review is outdated, your state of the art assessment is outdated. If new evidence shows that a better treatment option now exists, or that a risk you considered acceptable is no longer acceptable, you must reflect that.

This is why Article 61 links clinical evaluation, state of the art, and risk-benefit analysis together. They depend on current data. If the data is stale, all three are questionable.

When I review a CER with an old literature search, I do not only question the clinical evidence. I question whether the manufacturer understands what the state of the art currently demands. If they are not tracking the literature, how are they tracking clinical practice?

Building a Sustainable Process

The way to manage this is to integrate literature monitoring into your clinical evaluation lifecycle. It should not be a separate task assigned to someone when the CER needs updating.

Set a calendar-based review every twelve months. Even if no specific trigger occurred, check whether your literature review is still current. Document the check. If no update is needed, document why.

Link your vigilance monitoring to your clinical evaluation team. When a field safety notice is issued for a comparable device, the clinical evaluation team should be notified. They assess whether it affects the literature review.

Link your design change process to your clinical evaluation process. When a design change is approved, a trigger for literature review assessment is automatically generated.

Make currency a standing agenda item in your clinical evaluation review meetings. Ask: has anything changed since the last review that requires an update?

This does not require massive resources. It requires structure.

Closing Observations

Currency is not about perfection. It is about demonstrating that you remained aware of what was happening in the clinical landscape and that you made informed decisions about when to update your evidence base.

The manufacturers who manage this well do not search more often than others. They simply have clear triggers, document their decisions, and link their literature review to the rest of their clinical evaluation process.

The manufacturers who struggle treat literature reviews as isolated deliverables rather than as part of an ongoing evaluation system. They search once, write the CER, and assume the work is done. Then they face delays, nonconformities, and rework.

Your literature review will become outdated. That is inevitable. The question is whether you knew it was outdated, whether you checked, and whether you acted.

If you can answer yes to all three, you have a defensible position. If you cannot, you have a gap that will eventually be exposed.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.